Vixiar Medical Taking up Residence at The LaunchPort™ in Port Covington

Share Article

Cardiopulmonary Device Company Moves Headquarters to Baltimore

Vixiar Medical announced today that it will be moving its HQ office, which includes executive, engineering and manufacturing functions to The LaunchPort™ Accelerator at the City Garage in Port Covington. The LaunchPort™, and its affiliated operation The Factory™, provide a full range of manufacturing and business services to its Residents.

Vixiar Medical recently closed a $1.5 million financing round and is preparing for regulatory submissions and then commercial launch. Local investors included TEDCO and the Abell Foundation. "We are very excited about The LaunchPort™ concept and the services it brings us at this stage of our development,” said Kevin Thibodeau, CEO of Vixiar. “We are also committed to bringing jobs to the City of Baltimore and contributing to the growth of a robust medical technology community in the State of Maryland.” Vixiar will maintain an existing business development office in Anne Arundel County.

“We are excited to have Vixiar join us, as they are representative of the emerging high value medical technologies that the State and its institutions are capable of producing,” said Robert Storey, Managing Partner of The LaunchPort™. “This moves us forward towards our strategy of growing and anchoring medical technology manufacturing within the city of Baltimore”.

About The LaunchPort™ Accelerator
The LaunchPort™ is a second stage accelerator for medical technology companies that are nearing or have recently completed regulatory approval. It offers a full range of production capabilities that enable emerging growth companies to efficiently launch their products into the market.

About Vixiar Medical, Inc.
Vixiar Medical, Inc., develops non-invasive, cost effective devices and systems for monitoring cardiopulmonary diseases, particularly those with significant clinical and economic burden. The Company’s first product, Indicor™, is a handheld point of care device and digital platform for monitoring worsening heart failure. Headquartered in Annapolis, Maryland, the Company is a spin-out of Johns Hopkins. For more information, go to http://www.vixiar.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Kevin Thibodeau
Visit website